Resistance to melanoma in mice immunized with semiallogenic fibroblasts transfected with DNA from mouse melanoma cells

Journal of Immunology

Volumn 160, Issue 6, 1998, Pages 2915-2922

  De Zoeten, Edwin F ^a   Carr Brendel, Victoria ^a   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST; IMMUNIZATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; FIBROBLASTS; GENE THERAPY; H-2 ANTIGENS; IMMUNIZATION; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSFECTION; VACCINES, DNA;

EID: 0032520771     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Boon, T., J.-C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. Boon, T. 1993. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int. J. Cancer 54:177.
3. Boon, T. 1992. Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58:177.
4. Storkus, W. J., H. J. Zeh III, M. J. Maeurer, R. D. Salter, and M. T. Lotze. 1993. Identification of human melanoma peptides recognized by class I restricted tumors infiltrating T lymphocytes. J. Immunol. 151:3719.
5. Cavallo, F., F. D. Pierro, M. Giovarelli, A. Gulino, A. Vacca, A. Stoppacciaro, M. Forni, A. Modesti, and G. Forni. 1993. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53:5067.
6. Russell, S. J., S. A. Eccles, C. L. Flemming, C. A. Johnson, and M. K. L. Collins. 1991. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47:244.
7. Chakravarty, P. K., H. Fuji, M. M. Abu-hadid, S.-C. Hsu, and A. K. Sood. 1992. Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression: potential therapeutic implications. Cancer Immunol. Immunother. 35:347.
8. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
9. Mullen, C. A., M. M. Coale, A. T. Levy, W. G. Stetler-Stevenson, L. A. Liotta, S. Brandt, and R. M. Blaese. 1992. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 52:6020.
10. Aoki, T., K. Tashiro, S.-I. Miyatake, T. Kinashi, T. Nakano, Y. Oda, H. Kikuchi, and T. Honjo. 1992. Expression of murine interleukin 7 in a murine glioma cell-line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89:3850.
11. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. F. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
12. Asher, A. L., J. J. Mule, and A. Kasid. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
13. Blankenstein, T., Z. Qin, K. Uberla, W. Muller, H. Rosen, H.-D. Volk, and T. Diamantstein. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173:1047.
14. 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor by means of interferon-producing cells. Cancer Res. 53:1107.
15. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820.
16. Columbo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G. Parmiani. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
17. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
18. Bottazzi, B., S. Walter, D. Govoni, F. Colotta, and A. Mantovani. 1992. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 148:1280.
19. Hui, K. M., T. F. Sim, T. T. Foo, and A.-A. Oei. 1989. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J. Immunol. 143: 3835.
20. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:4068.
21. Nabel, G. J., D. Gordon, D. K. Bishop, B. J. Nickoloff, Z.-Y. Yang, A. Aruga, M. J. Cameron, E. G. Nabel, and A. E. Chang. 1996. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA 93:15388.
22. Donehower, L., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 19:215.
23. Harvey, M., M. J. McArthur, C. A. Montgomery, Jr., A. Bradley, and L. A. Donehower. 1993. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7:938.
24. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
25. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
26. De Smet, C., S. J. Courtois, I. Faraoni, C. Lurquin, J. P. Szikora, O. De Backer, and T. Boon. 1995. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 42:282.
27. Van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038.
28. Traversari, C., P. van der Bruggen, I. F. Leuscher, C. Lurquin, P. Chomez, A. van Pel, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene Mage-2 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
29. Brichard, V., A. van Pel, T. Wolfel, C. Wolfel, E. de Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.
30. Van den Eynde, B., O. Peeters, O. de Backer, B. Gaugler, S. P. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689.
31. Bakker, A. B. H., J. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdar. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J. Exp. Med. 179:1005.
32. Kawakami, Y., S. Eliyahu, C. H. Elgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into the tumor. Proc. Natl. Acad. Sci. USA 91:3515.
33. Wooster, R., A. Cleton-Jansen, N. Collins, J. Mangion, R. Cornelius, C. Cooper, B. Gusterson, B. Ponder, A. Von Deimling, O. Weistler, C. Cornelisse, P. Devilee, and M. Stratton. 1994. Instability of short tandem repeats (microsatellites) in human cancers. Nat. Genet. 6:152.
34. Merlo, A., M. Mabry, E. Gabrielson, R. Vollmer, S. B. Baylin, and D. Sidransky. 1994. Frequent microsatellite instability in primary small lung cancer. Cancer Res. 54:2098.
35. Orth, K., J. Hung, A. Gazdar, A. Bowcock, J. M. Mathis, and J. Sambrook. 1994. Genetic instability in human ovarian cancer cell lines. Proc. Natl. Acad. Sci. USA 91:9495.
36. + tumor cells. Cell 75:1227.
37. Shibata, D., M. A. Peinado, Y. Ivonov, S. Malkhosyan, and M. Perucho. 1994. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet. 6:273.
38. Kim, T. S., M. K. L. Collins, S. J. Russell, and E. P. Cohen. 1993. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma associated antigens prolongs the survival of tumor-bearing mice. Int. J. Cancer 55:865.
39. Kim, T. S., S. J. Russell, M. K. L. Collins, and E. P. Cohen. 1992. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma associated antigens. Int. J. Cancer 51:283.
40. Kim, T. S., and E. P. Cohen. 1994. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54:2531.
41. Sun, T., T. S. Kim, M. R. Waltz, and E. P. Cohen. 1995. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Cancer Gene Ther. 2:183.
42. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T-cell growth factor: parameters of production and quantitative microassay for activity. J. Immunol. 120-2027.
43. Allen, H., D. Wraith, P. Pala, B. Askonas, and R. A. Flavell. 1984. Domain interactions of H-2 class I antigens alter cytotoxic T-cell recognition sites. Nature 309:279.
44. Vile, R., and I. Hart. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:962.
45. Wigler, M., A. Pellicer, S. Silverstein, and R. Axel. 1978. Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 14:725.
46. Sugden, B., K. Marsh, and J. Yates. 1985. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol. Cell. Biol. 5:410.
47. Kim, T. S., and E. P. Cohen. 1994. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulates predetermined classes of anti-melanoma effector cells. J. Immunother. 16:24.
48. Smith, K. A. 1990. Interleukin-2. Sci. Am. 262:50.
49. Galvin, F., G. J. Freeman, Z. Razi-Wolf, W. Hall, Jr., B. Benacerraf, L. Nadler, and H. Reiser. 1992. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J. Immunol. 149:3802.
50. Kundig, T. M., M. F. Bachman, C. DiPaolo, J. L. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343.